Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

A CAR-T trial is one of several efforts that suggest there’s hope of treating the “worst imaginable childhood brain tumor,” ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all ...

An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Additionally, Seres plans to discuss with the FDA the potential for a single clinical study of SER-155 to serve as the efficacy basis for product approval, due to the substantial ... cancer patients ...

The Mass General Brigham Gene and Cell Therapy Institute, a hub of innovation dedicated to accelerating groundbreaking research, conducting clinical trials and developing FDA-approved treatments, ...

U.S. FDA approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s first cell therapy, a BCMA-directed CAR-T immunotherapy ...

Autolus Therapeutics ( (AUTL) ) has provided an announcement. Autolus Therapeutics has achieved a pivotal milestone with the FDA’s ...

AUCATZYL ® (obecabtagene autoleucel) approved by US FDA on November 8 ... where he led the development of the company’s allogeneic CAR T programs targeting CD70 in T-cell lymphomas and renal cell ...